We developed a novel complex made from therapeutic oligonucleotide CpG ODN and natural beta-glucan. When we applied this complex with influenza vaccine, immune stimulation due to the vaccine was dramatically increased for mice and monkey. This complex played a role of adjuvant and this technology can be used for a wide variety of field.
Researcher Information
JST CREST
Research Area : “Development of the foundation for nano-interface technology”
Research Theme : “Manipulation of nano interface of drug-delivery system and its application to vaccine for bird flu”
Journal Information
Published in “Proceedings of the National Academy of Sciences of the United States of America”
Authors
Kouji Kobiyamaa, Taiki Aoshi, Hirotaka Naritac, Etsushi Kurodab, Masayuki Hayashi, Kohhei Tetsutani, Shohei Koyamad, Shinichi Mochizuki, Kazuo Sakurai, Yuko Katakai, Yasuhiro Yasutomi,
Shinobu Saijoi, Yoichiro Iwakura, Shizuo Akira, Cevayir Coban, and Ken J. Ishii
Title
“Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticlulate TLR9 agonist”
doi: 10.1073/pnas.1319268111
Contact
[About Research]
Ken Ishii, M.D., Ph.D.
Project Leader, Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation
E-mail: 
http://www.nibio.go.jp/adjuvant/member-e.html
Kazuo Sakurai Ph.D.
Professor, Faculty of Environmental Engineering, The University of Kitakyushu
E-mail: 
http://www.sakurai-lab.jp/
[About Program]
Masashi Furukawa
Green Innovation Group, Department of Innovation Research, Japan Science and Technology Agency
E-mail: 